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Background Screening programmes are promoted to control transmission of and
prevent female reproductive tract morbidity caused by genital chlamy-
dia. The objective of this study was to examine the effectiveness of
register-based and opportunistic chlamydia screening interventions.
Methods We searched seven electronic databases (Cinahl, Cochrane Controlled
Trials Register, DARE, Embase, Medline, PsycINFO and SIGLE)
without language restrictions from January 1990 to October 2007
and reference lists of retrieved articles to identify studies published
before 1990. We included studies examining primary outcomes (pelvic
inflammatory disease, ectopic pregnancy, infertility, adverse preg-
nancy outcomes, neonatal infection, chlamydia prevalence) and
harms of chlamydia screening in men and non-pregnant and pregnant
women. We extracted data in duplicate and synthesized the data
narratively or used random effects meta-analysis, where appropriate.
Results We included six systematic reviews, five randomized trials, one non-
randomized comparative study and one time trend study. Five reviews
recommended screening of women at high risk of chlamydia. Two
randomized trials found that register-based screening of women at
high risk of chlamydia and of female and male high school students
reduced the incidence of pelvic inflammatory disease in women at
1 year. Methodological inadequacies could have overestimated the
observed benefits. One randomized trial showed that opportunistic
screening in women undergoing surgical termination of pregnancy
reduced post-abortal rates of pelvic inflammatory disease compared
with no screening. We found no randomized trials showing a benefit
of opportunistic screening in other populations, no trial examining
the effects of more than one screening round and no trials examining
the harms of chlamydia screening.
Conclusion There is an absence of evidence supporting opportunistic chlamydia
screening in the general population younger than 25 years, the most
commonly recommended approach. Equipoise remains, so high-
quality randomized trials of multiple rounds of screening with
biological outcome measures are still needed to determine the
balance of benefits and harms of chlamydia screening.
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Introduction
Chlamydia screening is widely promoted in high-
income countries as an intervention to prevent repro-
ductive tract morbidity, including infertility, in women
by reducing chlamydia transmission.1–3 A National
Chlamydia Screening Programme in England1 and
regional Infertility Prevention Programs in the United
States4 offer chlamydia screening to eligible, sexually
active individuals younger than 25 years when they
attend consultations at specified health care, or other,
settings. This approach is known as opportunistic scre-
ening (Box 1). The other main approach is register-
based screening (Box 1, also known as call–recall,
proactive or population based). Key features of register-
based screening are an up-to-date register of those
eligible for screening, which can be used to send pro-
active invitations for screening; identifying those who
have not responded to an invitation and sending remin-
ders; sending repeat invitations at regular defined
intervals; compiling regular reports of the coverage;
and follow-up of testing.5 Register-based chlamydia
screening is being piloted in three regions of the
Netherlands from 2008.6
The way in which screening services are organized
and delivered can affect their success. Regular screen-
ing and follow-up are needed to realize sustainable
population benefits.7 This might be particularly impor-
tant for communicable diseases where asymptomatic
and repeated infections are common.8 These require-
ments are difficult to achieve and monitor with
opportunistic approaches, which require the target
group to use health services regularly, practitioners to
offer repeat tests at appropriate intervals and admin-
istrative systems to track individuals attending multiple
screening venues. Opportunistic cervical cancer screen-
ing, offered in the 1960s and 1970s by general
practitioners and family planning clinics in the United
Kingdom, was ineffective.9 Older women at highest
risk were screened infrequently or not at all, whilst
those at low risk were screened repeatedly. The fall
in the death rate from cervical cancer, which began
before screening was introduced, did not accelerate
until an organized call–recall system, which increased
regular coverage to 80%, was introduced in 1988.10
The primary objective of a screening programme is
to reduce mortality or morbidity.5,9 The strength of
evidence supporting chlamydia screening as a popula-
tion-level intervention has, however, been chal-
lenged.11,12,13,14 The objective of this study was to
examine the research evidence about the effectiveness
of screening to prevent chlamydia-associated morbidity
and transmission systematically, with a focus on the
organizational approach.
Methods
Data sources and searches
We searched Cinahl, Cochrane Controlled Trials Reg-
ister, Database of Abstracts of Research Effectiveness,
Embase, Medline, PsycINFO and SIGLE from January
1990 to October 2007. We searched the reference lists of
included articles to identify additional relevant articles,
including those published before 1990. We had no
language restrictions. We used subject heading and
free text terms that combined Chlamydia trachomatis
infections or pelvic inflammatory disease with terms
for screening (Supplementary Information 1).
Box 1 Definitions used
Screening
Members of a defined population, who may not know they are at risk of a disease or its complications, are asked a question
or offered a test to identify those who are more likely to be helped than harmed by further tests or treatment.49
Screening programme
A continuing public health service that ensures screening is delivered at sufficiently regular intervals to a high enough
proportion of the target population to achieve defined levels of benefit at the population level, while minimizing harm.12
Register-based screening
Registers are used to identify and enumerate the target population (e.g. in a geographical area, practice list of a general
practitioner or members of a health maintenance organization), to send invitations for screening, to send reminders to
those who have not attended and to send regular repeat invitations at appropriate intervals. Invitations are sent to
individuals irrespective of their record of health service use. Also known as population, proactive, call–recall, cyclical, active
or systematic screening.49
Opportunistic screening
A health professional offers a screening test to patients attending health care or other defined settings for any reason.
Individuals who do not use relevant health services will not have an opportunity to be offered screening. The health
professional takes responsibility for repeating the test offer at appropriate intervals.49
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Study selection
We included studies reporting primary biological
outcomes of any approach to chlamydia screening
in adult women and men, and harms resulting
from screening. The following were considered as
primary outcomes: chlamydia incidence or prevalence;
pelvic inflammatory disease, ectopic pregnancy
and infertility; adverse pregnancy outcomes; neonatal
morbidity or mortality; and male infertility.
Psychological distress, partner violence and relation-
ship breakdown were considered as harms.
We included systematic reviews, randomized con-
trolled trials, non-randomized comparative studies and
observational time trend studies if they included data
from at least two time points before the introduction
of the intervention.15 Two reviewers screened titles
and abstracts to identify potentially relevant articles.
Full-text articles were then read independently.
Discrepancies were resolved by discussion to reach
consensus about the list of articles to include.
Data extraction and quality assessment
We used published definitions of opportunistic and
register-based screening to determine the approach
used in included studies (Box 1). Two independent
reviewers assigned the screening approach and
extracted data. Discrepancies were resolved by dis-
cussion, or by consultation with a third reviewer.
We used criteria published by the United Kingdom
National Institute for Health and Clinical Excellence
for each study design to assess the quality of
reporting of the study methods.15 Supplementary
Tables 1a–d shows the details of the quality assess-
ments and criteria.
Data synthesis and analysis
We used narrative methods to describe the evidence.
If two or more trials examined the same intervention
and outcome, we combined the results statistically in
a meta-analysis using a random effects model. We
examined statistical evidence of heterogeneity due to
between-trial variation using the I2 statistic.16
A detailed report of this study has been published.13
Results
Our literature searches identified 2323 unique refer-
ences (Figure 1). We screened 418 full-text articles and
Excluded, N=369 
Disease not relevant, n=2 
Topic not relevant, n=109 
Study design not relevant, n=106
Background only, n=44 
Cross-sectional/qualitative, n=100 
Other, n=8 
Excluded, N=1906 
Disease not relevant, n=45 
Topic not relevant, n=1577
Study design not relevant, n=268
Not obtained, n=13
Other, n=3 
Excluded, N=1622 
Duplicates
References identified 
N=3932 
References screened 
N=2310 plus 13 identified through 
hand searching 
Full manuscript
N=418 
Time trend studies 
N=1
Non-randomized trials 
N=1
Randomized trials
N=5
Systematic reviews 
N=6
Excluded, N=5 
  Uptake as outcome, n=1 
  Wrong intervention, n=3 
  Insufficient data, n=1 
Excluded, N=17
  No data points
  before intervention, n=17
Excluded, N=9 
  Uptake as outcome, n=7 
  Poor enrolment, n=2 
Excluded, N=5 
  Duplicate, n=2 
  Uptake as outcome, n=1 
  Poor reporting, n=2 
Figure 1 Flow diagram for results of electronic database and handsearching for articles on chlamydia screening
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excluded 369. Of the remaining 49 studies, we excluded
36 (Supplementary Table 2, References s1–s36).13
Seventeen of these were time trend studies that did
not report data from the time period before the intro-
duction of the screening intervention (s20–s36). Eight
were controlled trials for which the outcome was
screening uptake (s6, 7, 11, 13, 15–17, 19) and that
have been summarized elsewhere.13 We excluded two
literature reviews that informed recommendations
about screening in the United Kingdom (s1) and
updated recommendations in Canada (s2) because
there was no description, or reference to a description,
that could determine whether or not they were system-
atic reviews. We included six systematic reviews,17–22
five randomized trials,23–27 one non-randomized com-
parative study28 and one time trend study.29
We found no randomized controlled trials of the
effects of opportunistic chlamydia screening in non-
pregnant women, pregnant women in antenatal
clinics or men. We found no randomized trial
reporting the outcomes of infertility in women or
men, ectopic pregnancy, adverse pregnancy outcomes,
neonatal morbidity or mortality and no trials that
examined the effects of more than one round of any
screening intervention. We found no trials reporting
harms of chlamydia screening.
Systematic reviews
Four systematic reviews17–20 directly informed pub-
lished national guidelines on chlamydia screening in
Canada,17 Scotland,18 and the United States2 (Table 1).
The most recent review, by the United States Preventive
Services Task Force,20 updated an earlier full review.19
Four reviews were based on searches of multiple
electronic databases.18,19,21,22 Our literature searches
identified all studies cited by the reviews as evidence of
effectiveness. No review separated studies according to
the organizational approach to screening. Among five
reviews that assessed the same trial of a register-based
approach,23 two graded this as good evidence19,22 and
one as fair evidence17 to recommend screening of
women at high risk of chlamydia. The Scottish guide-
line recommended opportunistic testing of women at
high risk of chlamydia but noted that no randomized
trial supported this.18 This guideline is being updated.30
One review graded the same study as a low-quality
randomized trial with no recommendation.21 Three
reviews recommended chlamydia screening before
termination of pregnancy.18,21,22 Three reviews cited
evidence from ecological time trend studies as suppor-
tive evidence in favour of chlamydia screening
programmes.19,21,22
Register-based screening
We found three randomized controlled trials23–25 and
one non-randomized comparative study28 reporting
the effects of register-based chlamydia screening on
the incidence of pelvic inflammatory disease or on
chlamydia prevalence (Tables 2 and 3).
Effects on reproductive tract morbidity in
women
Two randomized controlled trials (3537 women
enrolled) found that the risk of pelvic inflammatory
disease in women invited to be screened was about half
that of control groups 1 year after a single round of
register-based screening [summary risk ratio 0.46, 95%
confidence interval (CI) 0.27–0.78, I2¼ 0%].23,24
There were biases in the design of both studies
(Tables 2 and 3, Supplementary Table 1a). In the
earliest published study,23 the authors used the register
of a health maintenance organization in the United
States to identify, invite and follow-up their target
population. Overall, 36 547 women were randomized
first to screening and control groups, and consent for
inclusion was sought if their responses to a postal
questionnaire showed them to be single, non-pregnant
and at high risk of chlamydia (score 43, based on
age424¼ 1, black race ¼ 2, nulligravid¼ 1, douching
in past 12 months¼ 1 and 52 sexual partners in past
12 months¼ 1). Women randomized to the screening
group only were also telephoned to increase the
number with a risk assessment and allow screening
appointments to be made. These practices changed the
planned ratio in intervention and control groups from
1:2 to 1:1.6 (total 2607). Sixty-four per cent of women
in the intervention group and an unknown proportion
in the control group were screened for chlamydia.
Østergaard et al.24 conducted a cluster randomized trial
in 17 high schools in Aarhus County, Denmark (8909
students). Sexually active female and male students
responding to the invitation were asked to collect urine
and/or vaginal specimens at home, or told that they
could be tested at a local health clinic. Response rates
were higher in those assigned to the intervention (32%
of those randomized) than control group (24%).
Participants in the intervention group were given
additional information about the importance of partner
notification if diagnosed with chlamydia.31 Ascer-
tainment of pelvic inflammatory disease was
unblinded, and loss to follow-up 1 year later was
nearly 50% (Supplementary Table 1a).
Effects on chlamydia transmission
Two randomized trials and one non-randomized
comparative study reported effects of register-based
screening on chlamydia prevalence, as a measure of
chlamydia transmission (Tables 2 and 3).24,25,28 There
were biases in all studies (Supplementary Table 1a),
and results could not be combined statistically because
of differences in the ways the data were collected and
reported. Østergaard et al.24 found fewer diagnosed
infections at follow-up in female students who had
been proactively invited to provide home-collected
vaginal specimens compared with controls who were
told that they could visit their general practitioner
(Tables 2 and 3). Cohen et al.28 compared infection
rates between three schools that had provided
chlamydia screening over a 3-year-period with a
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Table 1 Characteristics of systematic reviews of effectiveness of chlamydia screening on primary outcomes
Study
Search strategy and
dates Target population Review questionsa Total hits
Included
studiesa Evidence reviewed
Conclusions or
recommendations Comment
Davies
et al.17
Medline January 1983 to
December 1995
Update of 1984
Canadian Task Force on
the Periodic Health
Examination
Adolescents; women;
women with infertility;
women with ectopic
pregnancy
Does screening reduce
infection rates of C
trachomatis?
Not stated Not stated 201 references cited.
One RCT of effective-
ness of screening.
Five studies in pregnant
women.
Prevalence studies in
Canada
Fair evidence to recommend
screening of high risk groups.
Fair evidence to exclude routine
screening of the general popu-
lation
Well-designed randomized
community trial of screening
for chlamydia in asymptomatic
populations and follow-up eva-
luation of complications is
warranted
Important methodological
limitations not recognized
or taken into account.
Recommended screening
approach not described.
Identified lack of evidence
for screening populations
other than those at high
risk during period covered
by search
Stokes21 Medline, January 1980 to
July 1996
Embase, 1991– 96
Sexually active non-preg-
nant women in general
practice in the UK
Evidence for routine
(unselective) screening
Evidence for selective
screening
Evidence for screening
pre-TOP/IUD insertion
1045 24 Unselective screening: no
RCT; six economic eva-
luations supporting
screening at prevalence
above 6%; one time
trend analysis in
Sweden.
Selective screening: one
RCT in high risk
women; two economic
evaluations; one time
trend analysis in
Wisconsin.
Screening pre-TOP: one
RCT; seven cross-sec-
tional studies; three
non-randomized com-
parisons.
Screening pre-IUD
insertion: 1 non-
randomized and 1
uncontrolled study
Unselective screening in
general practice not recom-
mended.
Good evidence from one RCT
that selective screening can
reduce the incidence of PID.
Screening recommended.
Screening not recommended
Only one reviewer. Not all
important limitations
recognized or taken into
account.
Evidence from RCT of
register-based approach
generalized to opportunistic
screening in general
practice
SIGN17 Medline, Embase,
Cochrane Library,
Cinahl, Social Citation
Index
Dates not reported
Sexually active women
and men in Scotland
In what circumstances
should potential chla-
mydial infection be
sought routinely in
adults?
What is the optimal
management of patients
identified as being
chlamydia positive?
Not stated Not stated 176 references cited. Two
RCTs relevant to chla-
mydia screening cited
All women undergoing termina-
tion of pregnancy should be
screened.
Sexually active women under
25 and women over 25 with
new or more than two sexual
partners should be tested
opportunistically at health care
settings.
All patients attending GUM
clinics, all patients with STI
and sexual partners of those
with chlamydia should be
tested.
Sexual partners of people with
suspected chlamydia should be
tested
Did not identify all relevant
trials. Recommendations
based on observational stu-
dies showing increased risk
of chlamydial infection,
rather than evidence that
early detection and treat-
ment in particular groups of
patients reduces the risk of
complications.
Evidence from RCT of reg-
ister-based approach gener-
alized to opportunistic
screening in health care
settings
(continued)
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Table 1 Continued
Study
Search strategy and
dates Target population Review questionsa Total hits
Included
studiesa Evidence reviewed
Conclusions or
recommendations Comment
Honey21 Medline, PubMed,
Embase, 1980 to June
2000
Young sexually active
women
Does screening by any
method reduce: the
prevalence of chlamy-
dia?
Does screening reduce
the incidence of upper
tract infection?
4300 5 Reduction in chlamydia
prevalence: two time
trend analyses in
Sweden; one non-ran-
domized comparison in
schools in USA.
Reduction in PID: one
RCT in women request-
ing TOP; one RCT in
high risk women
Circumstantial evidence
that screening pro-
grammes are associated
with reductions in pre-
valence of PID and
incidence of ectopic
pregnancy.
Screening for chlamydia
using culture is effective
in preventing PID in the
short term
Papers independently
reviewed. Most
methodological limita-
tions recognized. Study
quality taken into
account in grade of
recommendation
Nelson et al.19 Medline, HealthStar,
Cochrane Library,
January 1994 to
November 1999
Review of references
Non-pregnant women;
pregnant women,
and men in the US
Does screening reduce PID
in non-pregnant
women?
Does screening reduce
the prevalence of
chlamydia?
1330 9 Reduction in PID: one RCT
in high risk women;
two time trend analyses
in Sweden.
Reduction in chlamydia
prevalence: no adequate
controlled studies; eight
uncontrolled studies
Good evidence that
screening women at risk
reduces the incidence of
PID and fair evidence
that community-based
screening reduces pre-
valence of infection.
Fair evidence that
screening women at low
risk could detect extra
cases, but small benefit.
No direct evidence that
screening men could
reduce the incidence of
new infections in
women
Review used for USPSTF
recommendations in
USA. Comprehensive
methods and evidence
tables. Only one
reviewer. English lan-
guage only. Not all
important methodologi-
cal limitations recog-
nized or taken into
account
Meyers et al.20 PubMed July 2000 to July
2005
Review of references
and discussions with
authors
Update of Nelson
et al.19
Non-pregnant women;
pregnant women,
and men in the US
As above, plus: does
screening for chlamy-
dial infection reduce
adverse health out-
comes in men, reduce
adverse health out-
comes in women, or
reduce the incidence of
infection in women?
452 1 Reduction in PID: one RCT
in female and male
school students (termed
high risk because of
age), with 1 year
follow-up in women
In non-pregnant women,
one poor quality RCT
supporting evidence
above.
No new randomized or
non-randomized pro-
spective controlled stu-
dies of screening men
for chlamydial infection
and the ability of
screening programmes
to reduce the incidence
of infection among
women
Review used for revised
USPSTF recommenda-
tions in USA. Only one
database searched. Two
independent reviewers.
English language only.
Ostergaard et al.24,31 not
taken into account as
evidence of male
screening contributing
to reduced PID in
women
GUM, genitourinary medicine; IUD, intra-uterine device; PID, pelvic inflammatory disease; RCT, randomized controlled trial; STI, sexually transmitted infection; TOP,
termination of pregnancy; USPSTF, United States Preventive Services Task Force.
aReview questions are those specified by the authors. Only questions and included studies directly related to evidence for the effectiveness of screening are included here.
Reviews also examined evidence for chlamydia prevalence, risk factors, accuracy of diagnostic tests and cost-effectiveness.
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Table 2 Characteristics of included studies, by screening approach, design and outcome
Study, Design, Dates Study population Intervention Control
Register-based screening
Scholes et al.23 Individual RCT
October 1990 to May 1992
Women, 18–34 years, health main-
tenance organization, USA.
Selected as being at high risk of
chlamydia
Invitation to be screened for chla-
mydia at a study health clinic.
Cervical swabs tested by EIA and
culture
Usual care
Women saw primary care physi-
cian as required
Østergaard et al.24 Cluster RCT
January 1997 to April 1998
Same trial as Østergaard et al.30
Women and men, mean age 18
years, 17 schools, Aarhus County,
Denmark
Home sampling kits sent. Urine or
vaginal specimen, NAAT test.
Information about chlamydia.
Partner notification for positive
cases
Usual care
Offer of free chlamydia testing at
STI clinic or other physician.
Information about chlamydia. No
partner notification advice
Hodgins et al.25
Cluster RCT
March 1996 to July 1998
Women and men in 14 Inuit vil-
lages of 120–1800 people, Canada
All adults encouraged to take urine
specimen to health centre. NAAT
test.
Multi-media sexual health
campaign
Existing services
Chlamydia testing offered oppor-
tunistically to women presenting
for cervical smears, antenatal
care, STI care
Cohen et al.,28
Cluster CCT
September 1995 to September
1998
9–12th grade students (15–18
years), eight schools, Louisiana,
USA
Five screening rounds 1995–98.
Urine specimens, NAAT test
Information about STI, conse-
quences, prevention. Partner
notification
Usual care 1995–97
Urine specimens for NAAT testing
1997–98.
Partner notification
Opportunistic screening
Giertz et al.,26
Individual RCT
September 1983 to September
1984
Women under 25 years requesting
abortion, one hospital, Sweden
Screening pre-op from cervix, cul-
ture and DFA. Doxycycline if
positive before surgery
Usual care
Diagnostic testing for chlamydia
post-op if pelvic infection sus-
pected clinically
Penney et al.27
Individual RCT
1995–96
Women requesting abortion, four
hospitals, Scotland, UK
Screening pre-op from cervix, EIA.
Doxycycline if positive. Referral to
STI clinic
Universal antibiotic prophylaxis
Doxycycline and metronidazole
Herrmann et al.29
Time trend study
1988–93
Database of chlamydia tests,
University Hospital, Uppsala,
Sweden
1988, STI prevention programme
started in Uppsala, Sweden.
Testing by culture
Time period before screening started
CCT, controlled clinical trial; DFA, direct fluorescent antibody test; EIA, enzyme immuno assay; NAAT, nucleic acid amplification test; RCT, randomized controlled trial;
STI, sexually transmitted infection.
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Table 3 Results from included studies
Study, Design, Dates Outcomes Randomized or enrolled Events Effect estimate (95% CIs)
Register-based screening
Scholes et al.23
Individual RCT
Incidence of PID per
10 000 wm at 1 year
Uptake of screening (%)
Randomized 36 547 women (ratio
1:2 intervention:control)
Enrolled 2607 women at high
risk (ratio 1:1.6 intervention:
control)
PID
Intervention: 9 (8/10 000 wm)
Control: 33 (18/10 000 wm)
Screening uptake:
Intervention 645/1009 (64% of
enrolled)
Control: not reported
Risk ratio
0.44 (0.20–0.90)
Not applicable
Østergaard et al.24
Cluster RCT
Screening uptake reported in30
Treatment for PID (%) at
1 year
Chlamydia prevalence (%) at
1 year
Uptake of screening (%)
Randomized Intervention: 2603
women, 1733 men Control:
2884 women 1689 men
Eligible responders (sexually
active) Intervention: 928
women, 442 men Control: 833
women, 246 men
Agreed to 1 year follow up
(women) Intervention: 867
women Control: 833 women
PID
Intervention: 9/443 (1.9%)
Control: 20/487 (5.3%)
Prevalence:
Intervention: 13/443 (2.6%)
Control: 32/487 (8.1%)
Screening uptake:
Intervention f: 867 (33% of
randomized)
Intervention m: 430 (25% of
randomized)
Control f: 63 (2% of randomized)
Control m: 4 (<1% of randomized)
Mean difference
3.4% (0.4 to 7.2%)
5.5% (0.95–10.0%)
Clustering accounted for
Comparison of percent
Women and men: P< 0.001
Hodgins et al.25
Cluster RCT
March 1996 to July 1998
Chlamydia prevalence
(per 1000) at 1 year
Uptake of screening (%)
14 villages randomized, two
excluded Intervention: 5250
Control: not reported
Prevalence
Intervention pre, post (per 1000): 37.1,
24.2
Control pre, post (per 1000): 28.1, 26.1
Screening uptake:
Intervention: f, 29%; m, 16%
Control: not reported
Odds ratio intervention group
post vs pre 0.65 (0.52–0.81)
Clustering, matched design, and
control group change not
accounted for
Cohen et al.28
Cluster CCT
September 1995 to September
1998
Chlamydia prevalence in
intervention and control
schools 1997–98 (%)
Uptake of screening (%)
Parental consent Intervention:
52–65% Control: 64%
Intervention: 1099 women,
1094 men Control: 2605
women, 2458 men
Prevalence
Intervention f: 58/562 (10.3%)
Intervention m: 19/588 (3.2%)
Control f: 168/1411 (11.9%)
Control m: 79/1242 (6.4%)
Screening uptake:
Year 1, 56%; year 2, 65%; year 3, 52%
Comparison of percent
Women: P40.05
Men: P< 0.01
Clustering not accounted for.
Opportunistic screening
Giertz et al.26
Individual RCT
September 1983 to September
1984
Post-abortal PID up to
4 weeks post-op (%)
560 women randomized Post-abortal PID
Intervention: 14/288 (5%)
Control: 25/259 (10%)
Risk ratio
0.50 (0.27–0.95)
Penney et al.27
Individual RCT
1995–96
Suspected PID 8 weeks
post-op (%)
1703 women randomized Suspected post-abortal PID
Intervention: 54/791 (6.8%)
Control: 35/755 (4.6%)
Risk ratio
1.47 (0.97–2.23)
Herrmann et al.29
Time trend study
1988–93
Chlamydia prevalence
(per 1000)
119 892 chlamydia test results
from 1985 to 1993
Prevalence
Pre-intervention f: 1985, 107 per 1000; 1987, 78 per 1000
Post-intervention f: 1988, 58 per 1000; 1993, 32 per 100
Pre-intervention m: 1985, 183 per 1000; 1987, 108 per 1000
Post-intervention m: 1988 105 per 1000, 1993, 71 per 1000
CCT, controlled clinical trial; RCT, randomized controlled trial; f, female; m, male; wm, woman months; mth, months; PID, pelvic inflammatory disease.
4
4
2
IN
T
E
R
N
A
T
IO
N
A
L
JO
U
R
N
A
L
O
F
E
P
ID
E
M
IO
L
O
G
Y
non-randomly selected group of five schools with no
screening. The infection rate in intervention compared
with control schools was lower at follow-up in boys but
not in girls (Tables 2 and 3). In both studies, there was
no baseline assessment or treatment in control groups,
so, at follow-up, both incident and prevalent infections
would be detected, whereas only incident infections
would be detected in intervention schools. Hodgins
et al.25 invited all adults in six Inuit villages in Canada
to provide urine specimens as part of an intensive
sexual health education and promotion campaign.
Chlamydia prevalence 1 year after screening in inter-
vention villages fell (Tables 2 and 3). In six comparison
villages where there was no campaign but opportunis-
tic testing was available, prevalence 1 year later had not
changed.
Opportunistic screening
Effects on reproductive tract morbidity in women
We found two randomized trials (2263 women)
investigating the effects of opportunistic chlamydia
screening on pelvic inflammatory disease in women
requesting surgical termination of pregnancy.26,27 In
women in Sweden offered pre-operative chlamydia
screening and treatment, the risk of post-abortal
pelvic inflammatory disease was about half that
in women in the control group who received
diagnostic testing if they had post-operative symp-
toms (risk ratio 0.50, 0.27–0.95, Tables 2 and 3).26
Details of randomization, concealment and blinding
of outcome assessment were not reported. The other
study compared a strategy of pre-operative screening
using an enzyme linked immunoassay followed by
treatment of positive cases with universal peri-
operative antibiotic prophylaxis in Scotland.27 The
study was terminated before reaching the required
sample size, but there was weak evidence of
more episodes of post-operative pelvic inflammatory
disease at 8 weeks with the screening strategy
than with universal prophylaxis (risk ratio 1.47,
0.97–2.23, Tables 2 and 3). Re-infection was not
assessed as an outcome, but partner management in
women randomized to screening was poor: of 45
women with positive chlamydia or gonorrhoea tests, 4
partners were documented to have received
treatment.27
Effects on chlamydia transmission
We included one ecological study that reported time
trends in diagnosed chlamydia rates in Uppsala
County, Sweden.29 Herrmann and Egger used micro-
biology records and population data before and after
chlamydia testing in health care settings became
widespread.29 In 1988, chlamydia became a notifiable
infection, and partner notification was mandatory.
Five youth clinics providing free chlamydia testing
and treatment were established, and there was a
publicity campaign. Chlamydia testing was also
available in other health care settings, but the
activities were not coordinated as a screening pro-
gramme. Chlamydia rates per 1000 tests were
reported by year for 3 years before opportunistic
testing became widely available (1985–87) and 6 years
after (1988–93). The chlamydia infection rate fell
in both time periods in both women and men.
An increase in male rates at the end of the study
period was noted as an indication of increasing
incidence.
Discussion
Our systematic review assessed evidence for the
effectiveness of chlamydia screening in preventing
chlamydia-associated morbidity or transmission of
infection. Trial reporting quality was generally poor,
and there were methodological weaknesses that could
have biased the results of all included studies. In two
randomized trials, a single round of register-based
screening was associated with a reduced incidence
of pelvic inflammatory disease in women at 1 year.
Information about the effects of any chlamydia
screening approach on transmission of infection was
difficult to interpret. Trials of opportunistic chlamydia
screening have only been conducted in women
undergoing surgical termination of pregnancy. We
found no evidence for the effectiveness of opportu-
nistic screening in any other population, of multiple
rounds of any screening approach or about the harms
of chlamydia screening (Table 4).
Strengths and weaknesses
The strengths of this review were that we conducted
comprehensive literature searches of multiple data-
bases without language restrictions, and used rigorous
methods to identify, appraise and synthesize the
evidence. It is, therefore, unlikely that we excluded
any important studies during the dates covered by the
search. The main weakness of the review was that
it was not possible to combine effect estimates sta-
tistically for most comparisons because of the small
numbers of studies, and differences in the interven-
tions, populations or data reporting. Incomplete
reporting of methods made it difficult to interpret
the findings of many studies.
Comparison with other systematic reviews
The results of our systematic review differ from
others,17–22 which concluded that there was fair or
good evidence to recommend chlamydia screening.
First, by stratifying results according to the organiza-
tional approach to chlamydia screening, we showed
that any evidence of a beneficial effect applied only
to register-based interventions, and this was limited
by poor trial quality. Second, we found some evidence
that chlamydia screening in men might contribute
to a reduction in the incidence of pelvic inflammatory
disease in women (Table 4). The cluster randomized
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Table 4 Summary of randomized controlled trial evidence of effects of chlamydia screening in non-pregnant women, pregnant women and men, on primary
outcomesa
Intervention Evidence assessed Result
Register-based chlamydia screening
Non-pregnant women at increased risk One randomized trial in women with high
scores on a risk assessment invited to
attend a physician’s office23
Reduction in pelvic inflammatory disease at 1 year
One randomized trial in 18 to 19-year-old
female and male high school
students invited to mail home-collected
specimens.24,31 Increased risk because
of young age
Reduction in pelvic inflammatory disease at 1 year
Non-pregnant women not at increased risk No randomized trials found
Men One randomized trial in 18- to 19-year-old
female and male high school students
invited to mail home-collected
specimens24,31
Reduction in pelvic inflammatory disease in
women at 1 year could have been contributed to
by screening and treatment of men as well as
women
Reduction in chlamydia rate in screened women at
1 year
No data about outcomes in men
Pregnant women No randomized trials found
Regular repeated invitations to women or
men to be screened for chlamydia
No randomized trials found
Harms of screening No randomized trials found
Opportunistic chlamydia screening
Non-pregnant women at increased risk No randomized trials found
Non-pregnant women not at increased risk No randomized trials found
Men No randomized trials found
Pregnant women No randomized trials found in women
continuing pregnancy
One trial in women undergoing surgical
termination of pregnancy, compared with
no screening26
Reduction in post-abortal pelvic inflammatory
disease at 4 weeks
One trial in women undergoing surgical
termination of pregnancy, comparing
antibiotic prophylaxis with screening and
treatment of positive cases27
Weak evidence of a reduction in post-abortal PID
in women given prophylaxis compared with
screening and treatment of positive cases
Regular repeated invitations to women or
men to be screened for chlamydia
No randomized trials found
Harms of screening No randomized trials found
aPrimary outcomes of chlamydia screening: incidence of short-term (PID) or long-term (tubal infertility or ectopic pregnancy) complications in women; adverse pregnancy
outcomes; neonatal morbidity; change in chlamydia prevalence.
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trial by Østergaard and colleagues31 involved both
male and female students. If we presume that
some students at least were in shared sexual net-
works, the reduction in pelvic inflammatory disease
in women24 could be attributed in part to screening
and treatment of chlamydia-infected men. The United
States Preventive Services Taskforce20 reviewed the
same trial but concluded that there were no studies
showing that chlamydia screening in men produces
benefits in women. New Canadian guidelines on
sexually transmitted infections noted a gap in the
evidence about chlamydia screening in men, citing
the US review.32 Third, we did not find the results of
time trend studies to be consistent with randomized
controlled trial results.19,21,22 The only eligible study
in our review showed that chlamydia rates were
falling in Uppsala County, Sweden, before opportu-
nistic testing became widespread.29
Interpretation of the evidence
It has been argued that further randomized trials
of the primary outcomes of chlamydia screening are
unnecessary.33 Our review suggests that clinical
equipoise remains because the quality of trials so far
does not allow the benefits or harms of chlamydia
screening to be quantified accurately enough.11,12,14
Both trials of register-based screening must have
overestimated the effect of screening:23,24 Chlamydia
trachomatis is implicated in about 30% of acute pelvic
inflammatory disease,34 so even if screening and
treatment could prevent all cases resulting from
ascending chlamydia, a halving of the overall risk
of pelvic inflammatory disease is implausible. Seven
of nine cases of pelvic inflammatory disease in the
trial by Scholes and colleagues23 were in women
tested for chlamydia, so the intervention did not
prevent these cases. Furthermore, results from women
at high risk of chlamydia in this trial might not
be generalizable to all women younger than 25
years, and additional contacts with those invited
for screening could have exaggerated uptake or
changed behaviours, which might have increased
differences in outcomes between groups. In the trial
by Østergaard et al.,24 open outcome assessment could
have increased the estimated effect if symptoms
were more likely to be assigned to pelvic inflamma-
tory disease in the unscreened group and to other
causes in the screened group. Differential enrolment
rates and high losses to follow-up might also have
resulted in systematic differences between interven-
tion and control groups. The large effects seen in trials
have not been replicated in observational studies.
Rates of hospitalization for pelvic inflammatory
disease among 28 000 new recruits in the United
States Army were similar in screened compared
with unscreened women after 18 months (relative
risk, adjusted for age, race, education and aptitude
0.94, 95% CI 0.69–1.29).35 This slight reduction
and the lower overall hospitalization (adjusted
relative risk 0.94, 95% CI 0.90–0.99) among screened
women could reflect an unmeasured ‘healthy
screenee’ effect.5
The ways in which the interventions examined could
have prevented pelvic inflammatory disease have not
been examined critically. A single screening test could
only have a substantial direct effect if most infections
detected were recently acquired and were treated
before causing upper genital tract inflammation. This
is unlikely because chlamydia persists asymptomati-
cally for up to 5 years after diagnosis,36 so most
infections in a previously unscreened population would
already have been present for some time and might
already have caused tubal damage. Alternatively, high
enough levels of screening uptake and partner notifica-
tion would interrupt community transmission and
reduce exposure. Once off screening uptake of 33%
among school students in half the schools in one
Danish community would probably not have reduced
transmission substantially,24 and health maintenance
organization members are not a geographical commu-
nity, so transmission is unlikely to have been
affected.23 Neither trial reported partner treatment
rates.23,24 In one trial that examined pre-abortion
screening, only 10% of male partners of women with
either chlamydia or gonorrhoea were treated.27
Mathematical models provide the only source of
information about how chlamydia screening would
prevent pelvic inflammatory disease in the long term.
In these models, the reduction in pelvic inflammatory
disease depends on reducing transmission at a popula-
tion level by yearly repeated screening, treatment and
partner notification to reduce the risk of exposure to
chlamydia, and not to an individual effect of interrup-
tion of ascending infection.37–39
Implications for chlamydia screening
programmes
Distinguishing between register-based and opportu-
nistic approaches is important for operational reasons
because the way in which a screening programme is
delivered in practice should reproduce the benefit to
the target population observed in clinical trials.5 In
the United States, the Preventive Services Task Force
requires direct evidence that the entire screening
service achieves the primary health outcome.40 In the
United Kingdom5,41 and New Zealand,42 national
screening committees require evidence of effectiveness
from high-quality randomized trials of the screening
programme that is to be delivered. In most countries
that recommend chlamydia screening of specified
groups of asymptomatic individuals, tests are offered
opportunistically, usually in health care settings. Our
review shows that published trials about opportunistic
chlamydia screening provide indirect short-term
evidence of inadequate quality. Even where opportu-
nistic screening services are coordinated nationally
EFFECTIVENESS OF CHLAMYDIA SCREENING 445
with defined service standards, coverage of regular
screening and outcomes of opportunistic screening are
difficult to measure because health service data on
screening uptake are not routinely linked to data
on chlamydia-associated complications and neither
data source is linked to population records. Current
data from the best-performing region in the National
Chlamydia Screening Programme in England show
that, in contrast to predicted uptake of 50%,43 only
2.5% of 16- to 24-year-olds were screened in the past
year,44 and chlamydia positivity rates remain at
10–11%.1 There are no performance indicators for
the primary outcomes.45 The Chlamydia Screening
Implementation project in the Netherlands will show
whether or not the uptake of a register-based
approach with repeated yearly screening invitations6
can achieve the results observed by Scholes et al. 23
and Østergaard et al.24
Implications for the evaluation of
chlamydia screening
Uptake of screening is not an adequate surrogate
endpoint for trials of chlamydia screening because the
level of coverage predicting a defined reduction in
morbidity or transmission is not known.46 Objective
endpoints, such as ectopic pregnancy or tubal infer-
tility, often require invasive diagnosis and are too
rare or delayed to be used realistically in trials. Pelvic
inflammatory disease is the most commonly used
biological outcome because it is the most frequent
acute complication of lower genital tract chlamydia
and is strongly associated with impaired fertility.34
Clinical diagnosis is, however, known to be insensitive,
non-specific and subjective.34,47 If misclassification
applies similarly to both screened and unscreened
groups, the effect size would be attenuated. The
diagnosis of lower abdominal symptoms could,
however, be different in screened and unscreened
women if the investigator is influenced by the
chlamydia screening status. Since practitioners usually
cannot be blinded to the screening allocation in trials,
symptoms reported in follow-up consultations should
be recorded in a standard way, with the final outcome
assessment made by an independent blinded
committee.
A reduction in chlamydia transmission, attributable
to screening, would provide good primary evidence of
effectiveness. Comparing chlamydia test positivity
after a single screening round biases the result in
favour of the screened group, which includes incident
infections, while infections in the control group
include prevalent infections that might have been
present before the trial started. Ideally, the effect of
chlamydia screening on chlamydia transmission
would be determined in a population in whom
prevalent infections had been detected and treated,
for example following a prevalence study with
high participation, follow-up, treatment and partner
notification rates. The chlamydia screening interven-
tion would then be implemented in randomly
assigned areas over two or more screening intervals.
The final comparison would be made between
screened and unscreened communities in a follow-
up prevalence survey.
This systematic review provides information about
the limitations of published evidence about the
effectiveness of chlamydia screening, which can be
used to inform future research and decisions about
the introduction of chlamydia screening programmes.
Where chlamydia screening interventions have
already been introduced, our findings can be used
to help design studies to determine the most effec-
tive way to deliver and monitor the outcomes
of chlamydia screening. Interventions that combine
the advantages of both register-based and oppor-
tunistic screening approaches could reach a higher
proportion of the target population than either
method alone.48 For example, regular postal invita-
tions could be supplemented with opportunistic offers
to eligible individuals who have not responded.
Alternatively, an initial opportunistic offer of testing
could be followed up by postal invitations to non-
attenders. The effectiveness and cost-effectiveness
of chlamydia screening require further evaluation
in randomized trials over multiple screening rounds
with primary biological endpoints to show that
the programme does more good than harm at
reasonable cost.
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